HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop
© Syed et al; licensee BioMed Central Ltd. 2011
Received: 3 July 2010
Accepted: 19 May 2011
Published: 19 May 2011
Stat3 is a cytokine- and growth factor-inducible transcription factor that regulates cell motility, migration, and invasion under normal and pathological situations, making it a promising target for cancer therapeutics. The hepatocyte growth factor (HGF)/c-met receptor tyrosine kinase signaling pathway is responsible for stimulation of cell motility and invasion, and Stat3 is responsible for at least part of the c-met signal.
We have stably transfected a human squamous cell carcinoma (SCC) cell line (SRB12-p9) to force the expression of a dominant negative form of Stat3 (S3DN), which we have previously shown to suppress Stat3 activity. The in vitro and in vivo malignant behavior of the S3DN cells was compared to parental and vector transfected controls.
Suppression of Stat3 activity impaired the ability of the S3DN cells to scatter upon stimulation with HGF (c-met ligand), enhanced their adhesion, and diminished their capacity to invade in vitro and in vivo. Surprisingly, S3DN cells also showed suppressed HGF-induced activation of c-met, and had nearly undetectable basal c-met activity, as revealed by a phospho-specific c-met antibody. In addition, we showed that there is a strong membrane specific localization of phospho-Stat3 in the wild type (WT) and vector transfected control (NEO4) SRB12-p9 cells, which is lost in the S3DN cells. Finally, co-immunoprecipitation experiments revealed that S3DN interfered with Stat3/c-met interaction.
These studies are the first confirm that interference with the HGF/c-met/Stat3 signaling pathway can block tumor cell invasion in an in vivo model. We also provide novel evidence for a possible positive feedback loop whereby Stat3 can activate c-met, and we correlate membrane localization of phospho-Stat3 with invasion in vivo.
Signal transducer and activator of transcription (Stat) proteins are a family of transcription factors that are activated by phosphorylation of a conserved tyrosine residue in response to a host of growth factors and cytokines. Phosphorylated Stat dimers translocate into the nucleus to activate of several target genes that are involved in diverse cellular processes such as cytokine signaling , cell proliferation and development , abnormal tumorigenesis [3–5], and suppression of the immune response in the tumor microenvironment . Stat3, one of seven members of the Stat family, has been most strongly implicated in tumorigenesis [3–5]. Stat3 regulated genes include cyclin D1  and c-myc , which are involved in cell proliferation; Bcl-XL , survivin , and Bcl-2 , which mediate apoptosis; several matrix metalloproteases involved in invasion [12–14]; and growth factors and cytokines such as VEGF  and HGF . Up- or down-regulation of many of these genes has obvious implications in the development of cancer. Constitutive activation of Stat3 has been observed in a number of human cancers and cancer cell lines . Given that no naturally occurring Stat3 mutations that result in constitutive activity have been identified, the persistent Stat3 activation in tumors is likely due to a differences in expression or activity of proteins that regulate Stat3 or signaling molecules involved in the Stat3 pathway. Potential candidates include suppressor of cytokine signaling (SOCS), a negative regulator of cytokine signaling that is silenced by methylation in some tumors [17, 18] and various receptor tyrosine kinases such as EGFR and c-met that are activated in cancers [19, 20]. More recent evidence indicates that Stat3 may be a required for the maintenance of stem cell-like characteristics of glioblastoma stem cells . Given the central role of stat3 in positively effecting multiple biological processes involved in malignant cell behavior, extensive effort has been made to target Stat3 and suppress its activity in cancer cells . One recent preclinical study using myeloid and B cell-specific targeting of Stat3 by siRNA showed that silencing Stat3 expression lead to a strong antitumor immune response .
Stat3 has a critical function in the development of skin cancer . Using both skin-specific Stat3 knockout models [25, 26], and a skin specific Stat3 gain of function transgenic model (K5.Stat3C mice) , we have shown in collaboration with the DiGiovanni laboratory that Stat3 is indispensable for the initiation, promotion and malignant progression stages of skin carcinogenesis. More recently it has been shown, using skin stem cell-specific knockout of Stat3, that Stat3 is required for survival of skin stem cells during tumor initiation in the mouse skin 2-stage chemical carcinogenesis protocol, and that it is indeed these stem cells that form the initiated cell population that eventually gives rise to tumors . These results are reviewed in [29, 30].
Malignant progression and tumor cell invasion are often the result of uncontrolled cell motility and adhesion. There is considerable evidence for a role for Stat3 signaling in cell migration and invasion under normal and pathological situations. Overexpression and activity of Stat3 has been linked to the invasion and metastasis of several cancers in humans, including cutaneous squamous cell carcinoma (SCC) [31, 32], colorectal adenocarcinoma , and melanoma . Stat3 activation is required for induction of genes encoding matrix metalloproteases-1, 2, and 9 (MMP-1, MMP-2, and MMP-9) [12–14], as well as several other genes important in the metastatic cascade. In addition, Stat3-deficient keratinocytes are unable to migrate, partly due to deregulated p130CAS phosphorylation , a protein which is involved in the formation of focal adhesion complexes and reorganization of the cytoskeleton. These studies, as well as our studies with mouse skin-specific Stat3 gain of function and knockout models [29, 30], suggest that Stat3 activation plays a critical role in the invasion and metastasis of carcinomas.
Scatter factor, or hepatocyte growth factor (HGF), can regulate cell survival, growth, migration, and angiogenesis upon binding its cell surface receptor, c-met . c-met is often constitutively active in human tumors [36–38], and HGF/c-met signaling is at least partially mediated by Stat3 [20, 39]. In particular, Stat3 is transiently phosphorylated after HGF treatment, likely mediated by Stat3/c-met direct or indirect interaction . Stat3 was coimmunoprecipitated with phosphorylated c-met from intact cells, and the specificity of this interaction was demonstrated in in vitro competition experiments with peptides mimicking the c-met docking sequence and Stat3 phosphorylation site . Activated Stat3 mediates signals downstream of the HGF/c-met pathway , and Stat3 has been shown to be essential for HGF-induced morphogenesis and for invasive behavior driven by c-met in both fibroblasts and breast carcinoma cells [39–41]. A Stat3 binding site has been identified in the HGF promoter and this site is required for Stat3-mediated activation of HGF transcription in breast epithelial cells [16, 42]. Overall, these observations suggest that positive feedback signals in the HGF/c-met/Stat3 signaling pathway could contribute to tumorigenesis.
In order to investigate the role of Stat3 in the induction of cell motility and invasion in greater detail, we have employed a cell culture model in which a dominant-negative form of Stat3 was expressed in a tumorigenic human skin SCC cell line, SRB12-p9 . Stat3α, the full-length form of Stat3, is abundant and is constitutively phosphorylated (active) in these cells. It has been reported that Stat3β, a naturally occurring Stat3 splice variant that lacks the C-terminal transcriptional activation domain, can act in a dominant-negative fashion to inhibit the transcriptional activity of Stat3α [44, 45]. It was subsequently shown that mutating the critical tyrosine 705 phosphorylation site to phenylalanine generated a form of Stat3β (Stat3β-Y705F) that could block DNA binding by all endogenous forms of Stat3 . In this study we compare the malignant characteristics of SRB12-p9 cells with that of stably transfected clones that express FLAG-tagged Stat3β-Y705F (S3DN cells), which have suppressed Stat3 activity . We confirm for the first time that interference with the HGF/c-met/Stat3 signaling pathway can block tumor cell invasion in an in vivo model, and we present evidence for a positive feedback loop between Stat3 and c-met. Finally we correlate membrane localization of phospho-Stat3 with invasion in vivo.
The human skin SCC cell line SRB12-p9 was derived by single cell cloning from SRB-12 cells (a gift from Dr. Janet Price, Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center). Cells were cultured in a humidified atmosphere at 5% CO2, in Dulbecco's Modified Eagle's Media-F12 supplemented with 10% fetal calf serum. Generation of the stable S3DN expressing SRB12-p9 cell lines and vector control cell lines was previously described .
Invasion and scattering assays
8 μm pore-sized membrane inserts for 12 well plates were coated with 50 μL of 1:25 diluted Matrigel basement membrane matrix (Becton Dickinson) following the manufacturer's protocol. 25,000 WT, NEO4 and S3DN cells were seeded in triplicate onto inserts and incubated for 10 hours at 37°C in 5% CO2. No chemo-attractant or serum gradient was used. After incubation, membranes were fixed with 4% paraformaldehyde for 20 minutes and stained with hematoxylin. Cells that migrated through the Matrigel to the bottom of the insert were photographed on a Nikon TE300 microscope and counted. For the scattering assay, cells growing in 10% FCS-containing media were treated with 100 ng/ml HGF for 24 or 48 hours and photographed with phase contrast at 100× magnification on a Nikon TE300 microscope. Percent cell scattering was determined by counting the total number of cells in a field (T), and the number of cells which were visually determined to have no cell-cell contacts (M) in the field, and applying the following formula: percent scattering = (M/T) × 100%. At least 6 fields were counted for each treatment group and the fields were marked on the bottom of the dish so that they could be located at the 24 and 48 hour time points.
Cells were lysed and tumors homogenized on ice in RIPA lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 mM EDTA, 1% NP-40, 1 mM PMSF, 1 mM Na-orthovanadate) supplemented with 40 μl complete protease inhibitor cocktail (Roche) according to manufacturer-provided instructions. Extracted protein was quantified using the BioRad Protein Assay kit. Proteins were separated by SDS acrylamide (4-20%) gel electrophoresis and transferred to nitrocellulose membranes (BioRad). Blots were blocked with 5% BSA for 1 hour at room temperature, followed by incubation overnight at 4°C with antibodies against phosphorylated forms of c-met (Tyr1234-1235) and Stat3 (Tyr705), total Stat3 (Cell Signaling Technology), total c-met and b-actin (Santa Cruz), and MMP-2 and MMP-9 (Chemicon). Blots were washed with TBS/0.1% Tween 20 and incubated with a horseradish peroxidase-conjugated secondary antibody for 1 hour at room temperature, followed by an additional 3 washes with TBS/0.1% Tween 20. Chemiluminescence detection was performed according to the manufacturer's instructions (Millipore) followed by exposure to X-ray film or using the Chemidoc gel documentation system (BioRad).
After overnight incubation in serum free media, cells were treated with 100 ng/ml HGF for 30 minutes prior to harvest, and lysed with the following immunoprecipitation buffer: 1% NP-40 in PBS with 40 μl complete protease inhibitor cocktail (Roche), 2 mM Na-orthovanadate, 10 μM lactacystin, 10 mM NaF. Cell lysates (500 μg for each sample) were rocked at 4°C for 1 hour, followed by centrifugation for 5 minutes to pellet cellular debris. Supernatants were collected and samples were precleared with Protein A/G Plus-Agrarose (Santa Cruz) and normal IgG (Santa Cruz) for 1 hour at 4°C, followed by centrifugation for 5 minutes at 20,000 g. Total Stat3 (Cell Signaling Technology) and c-met (Santa Cruz) antibodies were added at a dilution of 1:1000 to a total volume of 1 ml, and immunoprecipitations were performed at 4°C overnight with constant rocking. 20 μl of Protein A/G Plus-Agarose (Santa Cruz) beads were added, and the solution was allowed to rock for 4 hours at 4°C. Reactions were washed 3 times using immunoprecipitation buffer and then brought up in 6× Laemli buffer for protein electrophoresis and Western blot analysis.
Mouse xenograft model
Groups of 6-7 week old female athymic NCR Nu/Nu (nude) and SCID/bg mice were housed in a temperature and humidity controlled Association for Assessment and Accreditation of Laboratory Animal Care facility with a 12 hour light/dark cycle. All procedures were approved by the LSUHSC Institutional Animal Care and Use Committee in accordance with NIH guidelines. Mice were maintained on LM-485 diet (Harlan Teklad) and allowed access to food and water ad libitum. Mice were injected subcutaneously in the interscapular region with 1 × 106 cells in 0.1 ml PBS. The growth of the subcutaneous tumors was evaluated twice weekly by caliper. Animals were sacrificed and tumors were excised at the end of the experiment (21 days after cell injection) and fixed in 4% paraformaldehyde for histological observation, western blotting, and immunohistochemistry.
Immunohistochemical examination of tumors
Tumors were isolated and fixed in formalin and embedded in paraffin prior to sectioning. Paraffin sections of 4 μm were deparaffinized in xylene, 3 × 7 minutes, and rehydrated by stepwise washes in decreasing ethanol/H2O ratio (100% to 50%, followed by soaking in water). Sections were either stained with hematoxylin and eosin (H&E) or boiled for 1 minute for antigen retrieval. For immunohistochemical staining, sections were incubated in Superblock (Pierce) blocking reagent for 1 hour at room temperature. After washing 3× in PBS, slides were incubated for overnight at 4°C with antibodies against p-c-met (Tyr1234-1235), p-Stat3 (Tyr705), and total Stat3 (Cell Signaling Technology), total c-met (Santa Cruz), and MMP-2 and MMP-9 (Chemicon). Slides were photographed on a Nikon TE300 fluorescence microscope under oil immersion, at 600× magnification, with a CCD camera (Roper Scientific). Images were processed with IPLabs v3.55 software (Scanalytics).
The statistical significance between experimental values was assessed by Student's T test. A P value of < 0.05 was considered as statistically significant.
Expression of S3DN suppresses the invasion and HGF-induced scattering of SRB12-p9 cells
Because HGF has potent effects on the motility of keratinocytes, and since dermal fibroblasts produce HGF in the skin , we decided to examine the role of Stat3 signaling in HGF-induced motility. Cells were allowed to grow into colonies of 8-12 cells for several days, and then treated with 100 ng/mL human recombinant HGF (R&D Systems) for 24 and 48 hours. Motility was measured as the number of cells in a colony lacking cell-cell contact with their neighbors. WT and NEO4 cells responded to HGF treatment with nearly 50% of cells becoming motile by 24 hours and maintained that status up to 48 hours later (Figure 1C, D). However, DN2 and DN5 cells responded minimally to HGF treatment, with only 11-12% of total S3DN cells scattered at the 24 hour time point (Figure 1D).
Suppression of Stat3 reduces activity of c-met in vitro: evidence suggesting a positive feedback loop
S3DN inhibits the invasive potential of SCC cells in vivo
Expression of S3DN alters the localization of active Stat3 in the cell
S3DN reduces expression of MMP-2 and MMP-9, and inhibits c-met phosphorylation in vivo
Immunostaining and Western blot analysis of tumors for expression of phospho-c-met agreed with our in vitro results (Figure 2), where we also noted reduced phospho-c-met expression in DN2 tumors compared to WT (Figure 5, compare p-c-met panel to lower p-c-met panel, 5B,C). In fact, the intense membrane-specific localization, typical of activated c-met, that was observed in the WT tumors was absent in the DN2 tumors. Unexpectedly, we found that unlike in S3DN cells grown in culture, total c-met levels were diminished in DN2 tumors compared to WT (Figure 5A, far right panels, 5B,C).
S3DN interferes with c-met/Stat3 interaction
Given the cumulative evidence supporting Stat3 as a potential therapeutic target in cancer and that there are ongoing clinical trials testing Stat3 inhibitors , our group has attempted to better understand the molecular mechanisms of Stat3 activity and the role of HGF/c-met in transducing its signal. To this aim, we have used the S3DN system, which provides a workable cell culture model to study multiple aspects of Stat3 function in detail. Here we successfully demonstrate that even partial reduction in Stat3 activity is sufficient to restrict motility and invasion. S3DN (DN2 and DN5) cells were significantly less invasive in both in vitro and in vivo assays, and this phenotype was accompanied by marked suppression of MMP-2 and MMP-9 expression, c-met activity, as well as inhibition of Stat3/c-met interaction.
The expression of S3DN reduced HGF-induced scattering and invasion through Matrigel-coated membranes (Figure 1). This assay indicates that the motile phenotype of the P9WT cells in this context is cytokine dependent and mediated by Stat3, which is relevant for tumors growing in vivo where they respond to a variety of cytokines and growth factors from host cells or from autocrine stimulation. The lack of complete suppression of invasiveness for the S3DN tumors indicates less than full penetrance for the effect of S3DN expression. This can be attributed to the fact that there is still active Stat3 in the S3DN cells (Figure 4, data not shown). It is also possible that the percentage of attached and invasive tumors would have been even higher for the WT and NEO4 groups had the experiment been carried out for a longer time, since it is likely that those tumors designated as attached would have eventually become invasive if allowed to grow longer.
We originally hypothesized that the mechanism for the reduced invasive behavior of S3DN cells is due to a suppression of c-met-mediated events. c-met is frequently constitutively active in human tumors [36–38], and several reports have shown that Stat3 is one of the downstream effectors of HGF/c-met signaling [20, 39]. HGF treatment enhances Stat3 activity, likely due to an interaction between c-met and Stat3 . We show that expression of S3DN leads to reduced baseline as well as inducible c-met activity in S3DN cells and tumors (Figure 2, 4). Inhibition of c-met activity in S3DN cells is also associated with reduced localization of p-c-met to focal adhesions (Figure 2). These findings provide a strong indication for a positive feedback loop involving HGF, c-met, and Stat3. The existence of such a feedback loop is further supported by our finding that S3DN cells are less responsive to HGF-induced motility. An analysis of the levels of endogenous HGF secretion in S3DN cells by ELISA revealed no detectable difference between the WT, NEO4 and S3DN cell lines (data not shown). However, the levels of secreted HGF in these cells were difficult to compare since they were below the detection threshold of the ELISA (< 40 pg/ml). We note that based on numerous reports concerning the biological effects of HGF, which typically fall in the ED50 range of 20-100 ng/ml, we do not expect that these cells produce sufficient amounts of HGF to ellicit an autocrine response. Our initial hypothesis was supported by our finding that there was an interaction between Stat3 and c-met proteins, and that this interaction is reduced in cells that express S3DN (Figure 6). It is possible that Stat3/c-met interaction occurs through FAK, since there are known associations between c-met and FAK  and Stat3 and FAK . We did find an association between c-met and FAK in IP experiments, but there was no detectable difference in the degree of this interaction between WT and S3DN cells (data not shown). We speculate that S3DN is preventing the activation of c-met at the cell membrane by interfering with normal Stat3/c-met interaction, possibly by competing with Stat3 for binding to c-met.
Interestingly, we observed membrane localization of p-Stat3 (Tyr705) in WT and NEO4 tumors, but not in the S3DN tumors, which had only nuclear staining (Figure 4A). This is in line with our previously published results with human SCC samples where we observed p-Stat3 (Tyr705) staining at the cell membrane and nuclei in tumors, but only in nuclei in the immediately adjacent non-malignant skin . It is possible that the membrane localization of p-Stat3 (Tyr705) is specific to cells that are more malignant. Recent published reports indicate that there are potential non-nuclear functions for Stat3. The functional flexibility of Stat3 was outlined in a review published by Gao and Bromberg , specifically describing a non-transcriptional, cytoplasmic role that may potentiate cell motility. A Stat3-stathmin interaction has been documented , as well as Stat3 localization at focal adhesions with FAK and paxillin . A recent publication describes a metabolic function in the mitochondria that supports Ras-dependent transformation  and cellular respiration . These reports indicate non-nuclear roles for Stat3 that contribute to the oncogenic properties of cancer cells and that these functions are separate from tyrosine-phosphorylation dependent transcriptional activity. We provide further support for a novel function for Stat3 by describing invasive tumors with a distinct Stat3 membrane localization. Although we do see suppression of MMP-2 and MMP-9 expression, which is likely due to transcriptional downregulation caused by S3DN expression, we propose that Stat3 may also be acting at the membrane to enhance motility and invasion (Figure 6). We further speculate that the Stat3 protein engaged in the non-transcriptional function at the membrane may be exerting a fast-acting response to external activators, whereas the transcriptional activation of genes like the MMPs by nuclear Stat3 could be a slower mechanism to potentiate cell motility. Thus, it is possible that the transcriptional and non-transcriptional functions of Stat3 are working in concert to influence cell migration, especially in malignant, invasive cells.
The lack of diminished phospho-Stat3 staining in the S3DN cells appears at first contradictory to previous data showing a positive correlation between Stat3 phosphorylation and activity. However we suggest that the S3DN protein blocks endogenous Stat3 activity at a point downstream of its phosphorylation. We have previously shown that Stat3 DNA binding, as measured by EMSA, is reduced in the S3DN cells compared to WT cells, confirming that S3DN expression has a suppressive effect on Stat3 activity .
Our observation that S3DN tumors grew to similar size as WT and NEO4 tumors was unexpected. A previous report, using HT-29 colon carcinoma cells in mouse xenograft experiments, showed a reduction in tumor size for cells stably expressing a similar Stat3 dominant negative form compared to parental HT-29 tumors . One possible explanation for this discrepency could be the fact that the parental HT-29 cells, unlike the SRB12-p9 cells, were negative for constitutive activation of Stat3 in the absence of exogenously added growth factors. From our initial studies of the S3DN cells we observed that the proliferation rate was unaffected by S3DN expression in vitro, while sensitivity to exogenous growth factor deprivation was increased . We hypothesized that the partial suppression of Stat3 activity in the S3DN cells was sufficient to affect survival under growth factor deprived conditions, but not sufficient to affect proliferation rate. In the case of HT-29 cells, where dominant negative Stat3 expression appears to completely block Stat3 activity, the tumor size is reduced even though host supplied growth factors are present. To observe a similar effect in our system would likely require stronger suppression of Stat3 activity.
We have shown for the first time in an in vivo tumor model that the HGF/c-met/Stat3 signaling cascade is critically involved in the motility and invasion of cancer cells, and disruption of this pathway by expression of S3DN suppresses invasion, reduces c-met activity and inhibits c-met/Stat3 interaction. Tumor cells producing high levels of HGF can activate c-met by either autocrine or paracrine signaling mechanisms, which leads to Stat3 activation and gene transcription. Based on the indications for a positive feedback loop between c-met and Stat3, we speculate that abnormally high levels of c-met activation could trigger this loop and drive cells toward invasive behavior. We also show that there is a possible role for Stat3 at the cell membrane that contributes to the malignant phenotype of invading tumor cells. We must express a high degree of caution in generalizing these results to all tumor cell types or even to other skin SCC cells, since these findings are confined to a single cell line. It will be necessary to perform a similar series of experiments on other skin SCC cell lines, as well as other tumor cell types. Attempts to generate additional stably expressing S3DN cells using other skin-derived cell lines, and cell lines of other tumor types, have been unsuccessful so far. This is perhaps due to a S3DN-mediated suppression of proliferation and/or survival that is too strong in those cells. The SRB12-p9 cells are likely to be unique in having a very strong constitutive Stat3 activity when grown in the presence of serum, thereby allowing survival of stable S3DN clones. Never-the-less, based on these results we suggest that targeting the HGF/c-met/Stat3 pathway could be an especially effective strategy for cancer therapy. Future work will focus on exploring the interaction between Stat3 and c-met, and the relationship of the HGF/c-met/Stat3 signaling loop to the invasive potential of skin SCC cells.
We thank Dr. James Cardelli for helpful comments and protocols. We thank Joe Jones in the LSUHSC-S Department of Pathology Immunohistology Core Facility and Kathleen Llorens in the LSUHSC-S Microscopy Core Facility for expert technical assistance. Grant support for JLC from the Feist-Weiller Cancer Center, Louisiana Board of Regents, and NIH/NCI CA116324. ZS had a fellowship from the Louisiana Board of Regents.
- Ihle JN: The Stat family in cytokine signaling. Curr Opin Cell Biol. 2001, 13 (2): 211-10.1016/S0955-0674(00)00199-X.View ArticlePubMedGoogle Scholar
- Williams JG: STAT signalling in cell proliferation and in development. Curr Opin Genet Dev. 2000, 10 (5): 503-10.1016/S0959-437X(00)00119-2.View ArticlePubMedGoogle Scholar
- Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis. Oncogene. 2000, 19 (21): 2474-10.1038/sj.onc.1203527.View ArticlePubMedGoogle Scholar
- Bromberg J: Stat proteins and oncogenesis. J Clin Invest. 2002, 109 (9): 1139-View ArticlePubMedPubMed CentralGoogle Scholar
- Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE: Stat3 as an Oncogene. Cell. 1999, 98 (3): 295-10.1016/S0092-8674(00)81959-5.View ArticlePubMedGoogle Scholar
- Yu H, Kortylewski M, Pardoll D: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007, 7 (1): 41-10.1038/nri1995.View ArticlePubMedGoogle Scholar
- Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S, Weinstein IB: Constitutive Activation of Signal Transducers and Activators of Transcription 3 Correlates with Cyclin D1 Overexpression and May Provide a Novel Prognostic Marker in Head and Neck Squamous Cell Carcinoma. Cancer Res. 2002, 62 (12): 3351-3355.PubMedGoogle Scholar
- Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R: Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA. 2001, 98 (13): 7319-7324. 10.1073/pnas.131568898.View ArticlePubMedPubMed CentralGoogle Scholar
- Zushi S, Shinomura Y, Kiyohara T, Miyazaki Y, Kondo S, Sugimachi M, Higashimoto Y, Kanayama S, Matsuzawa Y: STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer. 1998, 78 (3): 326-330. 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
- Aoki Y, Feldman GM, Tosato G: Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2003, 101 (4): 1535-1542. 10.1182/blood-2002-07-2130.View ArticlePubMedGoogle Scholar
- Bhattacharya S, Ray RM, Johnson LR: STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J. 2005, 392 (2): 335-344. 10.1042/BJ20050465.View ArticlePubMedPubMed CentralGoogle Scholar
- Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, Bromberg JF: Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA. 2004, 101 (29): 10602-10607. 10.1073/pnas.0404100101.View ArticlePubMedPubMed CentralGoogle Scholar
- Itoh M, Murata T, Suzuki T, Shindoh M, Nakajima K, Imai K, Yoshida K: Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene. 2005, 25 (8): 1195-View ArticleGoogle Scholar
- Xie Tx, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S: Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene. 2004, 23 (20): 3550-10.1038/sj.onc.1207383.View ArticlePubMedGoogle Scholar
- Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Shumin Z, Wang T, Sinibaldi D, Coppola D, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002, 21 (13): 2000-10.1038/sj.onc.1205260.View ArticlePubMedGoogle Scholar
- Hung W, Elliott B: Co-operative Effect of c-Src Tyrosine Kinase and Stat3 in Activation of Hepatocyte Growth Factor Expression in Mammary Carcinoma Cells. J Biol Chem. 2001, 276 (15): 12395-12403. 10.1074/jbc.M010715200.View ArticlePubMedGoogle Scholar
- Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG: SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 2003, 101 (7): 2784-2788. 10.1182/blood-2002-06-1735.View ArticlePubMedGoogle Scholar
- Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG: SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001, 28 (1): 29-PubMedGoogle Scholar
- Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S, DiGiovanni J: Epidermal Growth Factor Receptor-Mediated Activation of Stat3 during Multistage Skin Carcinogenesis. Cancer Res. 2004, 64 (7): 2382-2389. 10.1158/0008-5472.CAN-03-3197.View ArticlePubMedGoogle Scholar
- Zhang Y, Wang L, Jove R, Vande Woude G: Requirement of Stat3 for HGF/SF-Met mediated tumorigenesis. Oncogene. 2002, 21 (2): 217-226. 10.1038/sj.onc.1205004.View ArticlePubMedGoogle Scholar
- Sherry MM, Reeves A, Wu JK, Cochran BH: STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells. 2009, 27 (10): 2383-2392. 10.1002/stem.185.View ArticlePubMedPubMed CentralGoogle Scholar
- Darnell JE: Validating Stat3 in cancer therapy. Nat Med. 2005, 11 (6): 595-596. 10.1038/nm0605-595.View ArticlePubMedGoogle Scholar
- Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, Lee H, Scuto A, Liu Y, Yang C, et al: In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol. 2009, 27 (10): 925-932. 10.1038/nbt.1564.View ArticlePubMedPubMed CentralGoogle Scholar
- Pedranzini L, Leitch A, Bromberg J: Stat3 is required for the development of skin cancer. J Clin Invest. 2004, 114 (5): 619-View ArticlePubMedPubMed CentralGoogle Scholar
- Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, DiGiovanni J: Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest. 2004, 114 (5): 720-View ArticlePubMedPubMed CentralGoogle Scholar
- Kataoka K, Kim DJ, Carbajal S, Clifford JL, DiGiovanni J: Stage-specific disruption of Stat3 demonstrates a direct requirement during both the initiation and promotion stages of mouse skin tumorigenesis. Carcinogenesis. 2008, 29 (6): 1108-1114. 10.1093/carcin/bgn061.View ArticlePubMedPubMed CentralGoogle Scholar
- Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, Itami S, Nickoloff BJ, DiGiovanni J: Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med. 2005, 11 (1): 43-10.1038/nm1162.View ArticlePubMedGoogle Scholar
- Kim DJ, Kataoka K, Rao D, Kiguchi K, Cotsarelis G, Digiovanni J: Targeted disruption of stat3 reveals a major role for follicular stem cells in skin tumor initiation. Cancer Res. 2009, 69 (19): 7587-7594. 10.1158/0008-5472.CAN-09-1180.View ArticlePubMedPubMed CentralGoogle Scholar
- Kim DJ, Chan KS, Sano S, DiGiovanni J: Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Molecular Carcinogenesis. 2007, 46 (8): 725-731. 10.1002/mc.20342.View ArticlePubMedGoogle Scholar
- Sano S, Chan KS, DiGiovanni J: Impact of Stat3 activation upon skin biology: A dichotomy of its role between homeostasis and diseases. J Dermatol Sci. 2008, 50 (1): 1-14. 10.1016/j.jdermsci.2007.05.016.View ArticlePubMedGoogle Scholar
- Suiqing C, Min Z, Lirong C: Overexpression of Phosphorylated-STAT3 Correlated with the Invasion and Metastasis of Cutaneous Squamous Cell Carcinoma. J Dermatol Sci. 2005, 32 (5): 354-360.View ArticleGoogle Scholar
- Clifford J, Walch E, Yang X, Xu X, Alberts D, Clayman G, El-Naggar A, Lotan R, Lippman S: Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clin Cancer Res. 2002, 8 (7): 2067-2072.PubMedGoogle Scholar
- Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T, Sekine I: Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol. 2005, 58 (8): 833-838. 10.1136/jcp.2004.023416.View ArticlePubMedPubMed CentralGoogle Scholar
- Kira M, Sano S, Takagi S, Yoshikawa K, Takeda J, Itami S: STAT3 Deficiency in Keratinocytes Leads to Compromised Cell Migration through Hyperphosphorylation of p130cas. J Biol Chem. 2002, 277 (15): 12931-12936. 10.1074/jbc.M110795200.View ArticlePubMedGoogle Scholar
- Gherardi E, Stoker M: Hepatocyte growth factor-scatter factor: mitogen, motogen, and met. Cancer Cells. 1991, 3 (6): 227-232.PubMedGoogle Scholar
- Cortner J, Vande Woode G, Rong S: The Met-HGF/SF autocrine signaling mechanism is involved in sarcomogenesis. EXS. 1995, 74: 89-121.PubMedGoogle Scholar
- Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, De Stefani A, Valente G, Giordano S, Cortesina G, Comoglio PM: Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene. 2000, 19 (12): 1547-1555. 10.1038/sj.onc.1203455.View ArticlePubMedGoogle Scholar
- Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R: c-MET Mutational Analysis in Small Cell Lung Cancer: Novel Juxtamembrane Domain Mutations Regulating Cytoskeletal Functions. Cancer Res. 2003, 63 (19): 6272-6281.PubMedGoogle Scholar
- Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C, Comoglio PM: Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature. 1998, 391 (6664): 285-288. 10.1038/34657.View ArticlePubMedGoogle Scholar
- Cramer A, Kleiner S, Westermann M, Meissner A, Lange A, Friedrich K: Activation of the c-Met receptor complex in fibroblasts drives invasive cell behavior by signaling through transcription factor STAT3. Journal of Cellular Biochemistry. 2005, 95 (4): 805-816. 10.1002/jcb.20459.View ArticlePubMedGoogle Scholar
- Cheng N, Chytil A, Shyr Y, Joly A, Moses HL: Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res. 2008, 6 (10): 1521-1533. 10.1158/1541-7786.MCR-07-2203.View ArticlePubMedPubMed CentralGoogle Scholar
- Wojcik EJ, Sharifpoor S, Miller NA, Wright TG, Watering R, Tremblay EA, Swan K, Mueller CR, Elliott BE: A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells. Oncogene. 2006, 25 (19): 2773-2784. 10.1038/sj.onc.1209306.View ArticlePubMedGoogle Scholar
- Yin W, Cheepala S, Roberts J, Syson-Chan K, DiGiovanni J, Clifford J: Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Molecular Cancer. 2006, 5 (1): 15-10.1186/1476-4598-5-15.View ArticlePubMedPubMed CentralGoogle Scholar
- Caldenhoven E, van Dijk T, Solari R, Armstrong J, Raaijmakers J, Lammers J, Koenderman L, de Groot R: STAT3beta, a Splice Variant of Transcription Factor STAT3, Is a Dominant Negative Regulator of Transcription. J Biol Chem. 1996, 271 (22): 13221-13227.PubMedGoogle Scholar
- Schaefer T, Sanders L, Nathans D: Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. Proc Natl Acad Sci USA. 1995, 92 (20): 9097-9101. 10.1073/pnas.92.20.9097.View ArticlePubMedPubMed CentralGoogle Scholar
- Schaefer TS, Sanders LK, Park OK, Nathans D: Functional differences between Stat3alpha and Stat3beta. Mol Cell Biol. 1997, 17 (9): 5307-5316.View ArticlePubMedPubMed CentralGoogle Scholar
- Gohda E, Kataoka H, Tsubouchi H, Daikilara Y, Yamamoto I: Phorbol ester-induced secretion of human hepatocyte growth factor by human skin fibroblasts and its inhibition by dexamethasone. FEBS Letters. 1992, 301 (1): 107-10.1016/0014-5793(92)80220-B.View ArticlePubMedGoogle Scholar
- Syed Z, Cheepala SB, Gill JN, Stein J, Nathan CA, DiGiovanni J, Batra V, Adegboyega P, Kleiner HE, Clifford JL: All-trans retinoic acid suppresses Stat3 signaling during skin carcinogenesis. Cancer Prevention Research. 2009, 2: 903-911. 10.1158/1940-6207.CAPR-09-0041.View ArticlePubMedGoogle Scholar
- Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, et al: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA. 2003, 100 (7): 4138-4143. 10.1073/pnas.0534764100.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen SY, Chen HC: Direct Interaction of Focal Adhesion Kinase (FAK) with Met Is Required for FAK To Promote Hepatocyte Growth Factor-Induced Cell Invasion. Mol Cell Biol. 2006, 26 (13): 5155-5167. 10.1128/MCB.02186-05.View ArticlePubMedPubMed CentralGoogle Scholar
- Silver DL, Naora H, Liu J, Cheng W, Montell DJ: Activated Signal Transducer and Activator of Transcription (STAT) 3: Localization in Focal Adhesions and Function in Ovarian Cancer Cell Motility. Cancer Res. 2004, 64 (10): 3550-3558. 10.1158/0008-5472.CAN-03-3959.View ArticlePubMedGoogle Scholar
- Gao SP, Bromberg JF: Touched and Moved by STAT3. Sci STKE. 2006, 2006 (343): pe30-10.1126/stke.3432006pe30.PubMedGoogle Scholar
- Ng DCH, Lin BH, Lim CP, Huang G, Zhang T, Poli V, Cao X: Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol. 2006, 172 (2): 245-257. 10.1083/jcb.200503021.View ArticlePubMedPubMed CentralGoogle Scholar
- Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE: Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation. Science. 2009, 324 (5935): 1713-1716. 10.1126/science.1171721.View ArticlePubMedPubMed CentralGoogle Scholar
- Wegrzyn J, Potla R, Chwae YJ, Sepuri NBV, Zhang Q, Koeck T, Derecka M, Szczepanek K, Szelag M, Gornicka A, et al: Function of Mitochondrial Stat3 in Cellular Respiration. Science. 2009, 323 (5915): 793-797. 10.1126/science.1164551.View ArticlePubMedPubMed CentralGoogle Scholar
- Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, et al: Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia. 2005, 7 (6): 545-555. 10.1593/neo.04571.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/180/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.